Physician profile
David Chube
NPI 1124024096
$2,524.32
in general payments reported to CMS, 2019-2025
15 companies · $484 in 2025
The $484 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $232 · 2021: $210 · 2022: $153 · 2023: $399 · 2024: $479 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,360.90 | 2019-2025 | Grafix Pl, Collagenase Santyl, Pico |
| Mimedx Group, INC. | $287.28 | 2024-2025 | |
| Urgo Medical North America, LLC | $214.78 | 2024-2025 | Urgoclean Ag, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Surgenex LLC | $131.83 | 2025 | Renograft, Surgraft, Ardeograft |
| Organogenesis INC. | $99.25 | 2024-2025 | Via Matrix, Apligraf |
| Astrazeneca Pharmaceuticals LP | $95.25 | 2019 | |
| Kci USA, INC. | $73.97 | 2023 | 3m Coban, Promogran Prisma, Kerramax Care |
| Paratek Pharmaceuticals, INC. | $63.19 | 2024-2025 | Nuzyra |
| Pfizer INC. | $61.04 | 2019 | |
| Aroa Biosurgery Incorporated | $38.16 | 2019 | |
| Medline Industries LP | $28.72 | 2020 | |
| Integra Lifesciences Corporation | $19.73 | 2022 | |
| Solventum Corporation | $16.93 | 2025 | Activ.A.C. |
| Convatec INC. | $16.69 | 2023 | |
| Dexcom, INC. | $16.60 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.